Jun Guo

OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study

Chuanliang Cui, Xuan Wang, Bin Lian et al. · Journal for ImmunoTherapy of Cancer · 2022 · 55 citations · Full text

Medicine, Immunology, Oncology +17

Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial

Jiayong Liu, Xuan Wang, Zhongwu Li et al. · Signal Transduction and Targeted Therapy · 2024 · 31 citations · Full text

Medicine, Oncology, Surgery +17

Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights

Hui Tian, Zhihong Chi, Lu Si et al. · Journal for ImmunoTherapy of Cancer · 2025 · 21 citations · Full text

Medicine, Clinical Sciences, Oncology +17

A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma

Lili Mao, Jun Guo, Lingjun Zhu et al. · European Journal of Cancer · 2022 · 17 citations

Medicine, Oncology, Pharmacology +15

Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma

Qian Zhao, Teng Wang, Huanhuan Wang et al. · Frontiers in Pharmacology · 2022 · 14 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15